- Home
- Publications
- Publication Search
- Publication Details
Title
Phosphodiesterase 4-targeted treatments for autoimmune diseases
Authors
Keywords
Autoimmune, Apremilast, Crohn’s, Dermatitis, PDE4, Psoriasis, SLE
Journal
BMC Medicine
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2013-04-04
DOI
10.1186/1741-7015-11-96
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
- (2012) Ejaz Pathan et al. ANNALS OF THE RHEUMATIC DISEASES
- Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
- (2012) Georg Schett et al. ARTHRITIS AND RHEUMATISM
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
- (2012) Kim Papp et al. LANCET
- Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor
- (2012) Thérèse Keravis et al. PLoS One
- Imaging in Axial Spondyloarthritis
- (2012) Xenofon Baraliakos et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
- (2011) D. van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
- (2011) J. Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis
- (2011) Robert P. Baughman ARCHIVES OF DERMATOLOGY
- Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis
- (2011) Praveena Chiowchanwisawakit et al. ARTHRITIS AND RHEUMATISM
- Disposition, metabolism and mass balance of [14C]apremilast following oral administration
- (2011) Matthew Hoffmann et al. XENOBIOTICA
- Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
- (2010) P. Machado et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation
- (2010) L. SEKUT et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species
- (2010) Rodrigo Guabiraba et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Apoptosis Inhibition Can Be Threatening in Aβ-Induced Neuroinflammation, Through Promoting Cell Proliferation
- (2010) A. Abdi et al. NEUROCHEMICAL RESEARCH
- Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
- (2010) Fiona E McCann et al. ARTHRITIS RESEARCH & THERAPY
- Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
- (2009) Tsutomu Akama et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release
- (2009) WK Ong et al. BRITISH JOURNAL OF PHARMACOLOGY
- Regulation of AMP-activated protein kinase by cAMP in adipocytes: Roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis
- (2009) Bilal Omar et al. CELLULAR SIGNALLING
- The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue
- (2009) Roberta L. Gonçalves et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease
- (2009) J.N. Gordon et al. Journal of Crohns & Colitis
- Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
- (2009) Hon-Wah Man et al. JOURNAL OF MEDICINAL CHEMISTRY
- Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
- (2009) Peter MA Calverley et al. LANCET
- Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects
- (2009) Fanny Monneaux et al. ARTHRITIS RESEARCH & THERAPY
- Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
- (2008) S Visvanathan et al. ANNALS OF THE RHEUMATIC DISEASES
- PDE4 inhibitors: current status
- (2008) D Spina BRITISH JOURNAL OF PHARMACOLOGY
- An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
- (2008) A. B. Gottlieb et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models
- (2008) Daisuke Harada et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model
- (2008) Daisuke Harada et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Systemic Lupus Erythematosus
- (2008) Anisur Rahman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
- (2008) Xenofon Baraliakos et al. ARTHRITIS RESEARCH & THERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started